The Biological Computing Co.
Category: AI Infrastructure
An applied biological computing company that uses living neurons to discover algorithms and software adapters that make frontier AI models more stable, scalable, and efficient. The Biological Computing Co. was founded in 2022. The company is led by Alexander Ksendzovsky. Based in San Francisco & Baltimore, USA. Team size: 10-50. Total funding raised: $25.0M. Latest round: Seed. Key investors include Primary Venture Partners, Builders VC, E1 Ventures, Proximity, Refactor Capital, Tusk Ventures, Wonder Ventures.
- Founded
- 2022
- Headquarters
- San Francisco & Baltimore, USA
- Team size
- 10-50
- Total funding
- $25.0M
Value proposition
Translates insights from living neural networks into lightweight software adapters and optimization methods that improve AI model quality, speed, and inference cost on conventional GPU/cloud infrastructure—without requiring biological hardware for end users.
Products and solutions
Algorithm Discovery Platform (neuron experiments → AI algorithms), Neural Dynamics / Biological Adapters (software modules for generative video & CV), TBC Neural Optimizer (neurally-optimized model software), Neurally-optimized video models (OASIS 500M PoC; commercial text-to-video planned)
Unique value
Unlike neuromorphic chips or brain-inspired algorithms, TBC empirically derives computational principles from living neurons on multi-electrode arrays and ships them as deployable software adapters that improve existing AI models on standard GPUs.
Target customer
AI developers and frontier labs, AI infrastructure/cloud providers, and brands seeking to optimize video generation, computer vision, and custom models without full retraining.
Industries served
Artificial Intelligence Infrastructure, Biotechnology, Cloud Computing, Sustainability & Green Tech
Technology advantage
Uses living neuron cultures on MEAs to discover computational principles, then ships lightweight software adapters (~100k–params class) that improve model quality/cost on standard GPUs—combining biological moat with digitally scalable GTM.
How they differentiate
Near-term product is software (biologically derived adapters/optimizers) that improves video and vision models without replacing silicon; longer-term path is real-time biocompute. Differs from Cortical Labs/FinalSpark wetware-as-a-service by delivering digitally scalable model improvements derived from neuron experiments.
Main competitors
Cortical Labs, FinalSpark, Koniku
Key partnerships
NVIDIA Inception Program, University of Maryland School of Medicine, Bluesky Compute (PoC inference hosting), Shaul Druckmann (Stanford Neuroscience Advisor), Richard Holden (ex-Google Product & Partnerships Advisor), Primary Venture Partners, Builders VC, Refactor Capital, E1 Ventures
Notable customers
University of Maryland School of Medicine (Research Partner)
Major milestones
Raised $25M Seed led by Primary Venture Partners (Feb 2026); opened SF Mission Bay lab, Appointed advisors Shaul Druckmann (Stanford) and Richard Holden (ex-Google) (May 2026); team ~25 FTE, First paying customer for biological compute (reported Jun 2026 by Refactor Capital), Released OASIS 500M neurally-optimized software PoC with Bluesky Compute (Jul 2026); commercial optimized video model planned later 2026, NVIDIA Inception member; CEO received ABTA Lucien Rubinstein Award (2009)
Growth metrics
Commercialization phase: ~25–32 employees (May–mid 2026); public OASIS Neural Optimizer PoC (2x quality, 4.4x lower inference cost); first paying biological-compute customer reported; commercial neurally-optimized video model planned for later 2026.
Market positioning
Deep-tech AI infrastructure / algorithm-discovery company: biology-derived software today, biological computing substrate tomorrow.
Geographic focus
North America (HQ in San Francisco) with global reach via proposed cloud-based biological computing access.
Patents and IP
Proprietary IP surrounding the 'Bionode' architecture and biological-digital interface adapters (specific patent numbers not publicly disclosed).
About Alexander Ksendzovsky
Alexander Ksendzovsky is a neurosurgeon-scientist and entrepreneur. He is an Associate Professor of Neurosurgery and Director of Epilepsy Surgery at the University of Maryland School of Medicine. He holds an MD from Chicago Medical School and a PhD in Neuroscience from the University of Virginia, followed by a fellowship at Yale School of Medicine. He previously co-founded NeuroRPM, a digital health company utilizing AI for Parkinson's monitoring.
Latest news about The Biological Computing Co.
- The Biological Computing Co. (TBC) secured 25 million USD in seed funding to develop AI powered by living neurons instead of pure silicon. By integrating lab-grown brain cells with modern infrastructu
- The Biological Computing Co. raised $25M to replace silicon with living neurons, tackling the energy crisis of the AI boom. By encoding data into electrical patterns for neurons, TBC achieves pattern
More AI Infrastructure companies
Official website: https://www.tbc.co/
